以下是目前公布的肝癌肿瘤突变抗原肽清单，该清单均支持定制生产 (定制咨询请扫描本页右侧联系人二维码)。可定制生产：
- 检测或分选抗原特异性T细胞的流式试剂、磁珠分选试剂
- 构建抗原肽和MHC复合物，用于合成人工呈递物，从而刺激T细胞增殖
| 抗原蛋白 | 抗原肽 | 呈递抗原的HLA | 验证文献 |
|---|---|---|---|
| Receptor tyrosine-protein kinase erbB-2 | IISAVVGIL | HLA-A2 | Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007 |
| HER2 receptor | TYLPTNASL | HLA-A24 | Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007 |
| Receptor tyrosine-protein kinase erbB-2 | IISAVVGIL | HLA-A2 | Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007 |
| HER2 receptor | TYLPTNASL | HLA-A2 | Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 2007 |
| glypican 3 | FVGEFFTDV | HLA-A*02:01 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | EYILSLEEL | HLA-A*24:02 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | FVGEFFTDV | HLA-A*02:01 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | EYILSLEEL | HLA-A*24:02 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | EYILSLEEL | HLA-A*24:02 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | EYILSLEEL | HLA-A*24:02 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | EYILSLEEL | HLA-A*24:02 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | EYILSLEEL | HLA-A*24:02 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| glypican 3 | EYILSLEEL | HLA-A*24:02 | Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 2017 |
| Chromodomain-helicase-DNA-binding protein 3 | AVMRWGMPL | HLA-A*02:01 | Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018 |
| MYO18A protein | VQLEEEYEV | HLA-A*02:01 | Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018 |
| Chromodomain-helicase-DNA-binding protein 3 | AVMRWGMPP | HLA-A*02:01 | Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018 |
| Programmed cell death protein 7 | VMLEGEQEA | HLA-A*02:01 | Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018 |
| Programmed cell death protein 7 | VMLEGEQEE | HLA-A*02:01 | Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. J Transl Med 2018 |
| Cytoplasmic dynein 1 heavy chain 1 | TLFSALWAL | HLA-A*02:06 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| Cytoplasmic dynein 1 heavy chain 1 | TLFSALWAL | HLA-A*02:06 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| hCG2043250, isoform CRA_b | WVMPVIPAL | HLA-A*02:06 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| hCG2043250, isoform CRA_b | WVMPVIPAL | HLA-A*02:06 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| E3 ubiquitin-protein ligase TRIM68 | RLRKRNEYR | HLA-A*31:01 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| ATP-binding cassette sub-family A member 2 | FLLPSGMAL | HLA-C*03:04 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| Sodium-independent sulfate anion transporter | LMRDHMPPV | HLA-A*02:03 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| Casein kinase I isoform alpha | YMYLRQLFHI | HLA-A*02:01 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| Casein kinase I isoform alpha | YMYLRQLFHI | HLA-A*02:01 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut 2021 |
| Cytochrome b | SPWWNFGSLL | HLA-A*24:02 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Protein SSX2 | ATLPPFMCNK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Glypican-3 | LQSASMELK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Glypican-3 | VVSQIIDKLK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | VRSLLRSHYR | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | FYVTETTFQK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | TTFQKNRLFFY | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | ALFSVLNYER | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | RAWRTFVLR | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | STLTDLQPY | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | KLFGVLRLK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | RTAQTQLSR | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Alpha-fetoprotein | ITVTKLSQK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Serpin B4 | ALGMVLLGAK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Serpin I2 | VLVNAIYFK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Serpin B3 | GLVLSGVLHK | HLA-A*11:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Cancer/testis antigen 1 | AMPFATPMEA | HLA-A*02:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Telomerase reverse transcriptase | LLRSFFYV | HLA-A*02:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Alpha-fetoprotein | FLYAPTILLW | HLA-A*02:01 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Protein SSX7 | KYEAMTKLGF | HLA-A*24:02 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Alpha-fetoprotein | KWVESIFLIF | HLA-A*24:02 | Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021 |
| Multiple inositol polyphosphate phosphatase 1 | YPTVKQICKL | HLA-B*07:02 | Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci 2022 |
| Mitochondrial 2-oxodicarboxylate carrier | LLMMTIASV | HLA-A*02:07 | Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci 2022 |
| Cell adhesion molecule 2 | TLMTATVTT | HLA-A*02:07 | Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci 2022 |
